Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%

Allergan

Status: Completed

Conditions: Dry Eye Disease

Treatments: Drug: Cyclosporine Ophthalmic Emulsion 0.05%

Study type: Observational

Funder types: Industry

Identifiers

NCT00827255

MA-RES-08-002

Details and patient eligibility

About

The objective of this retrospective chart review is to evaluate the patient characteristics, treatment variations and efficacy of a second trial of Cyclosporine Ophthalmic Emulsion 0.05% therapy in chronic dry eye patients who were initially treated with Cyclosporine Ophthalmic Emulsion 0.05% but discontinued use after less than 12 weeks of treatment.

Enrollment: 35 patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults >16 years of age
• Dry eye patients
• Subject with history of less than 12 weeks of initial RESTASIS® treatment
• Subject started second trial of RESTASIS® treatment prior to June 1, 2008
• First day of second trial of RESTASIS® started ≥ 4 weeks after the last day of previous RESTASIS® treatment

Exclusion criteria

• Patients with Contact Lens Intolerance
• Patients with Ocular Rosacea

Trial design

35 participants in 1 patient group

Patients who received Restasis®

Description:

Patients who received Restasis® (cyclosporine ophthalmic emulsion 0.05%)

Treatment:

Drug: Cyclosporine Ophthalmic Emulsion 0.05%